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Abstract
Background: HIV-1 integrase (IN) variability in treatment naïve patients with different HIV-1 subtypes is a major
issue. In fact, the effect of previous exposure to antiretrovirals other than IN inhibitors (INI) on IN variability has not
been satisfactorily defined. In addition, the genetic barrier for specific INI resistance mutations remains to be
calculated.
Methods: IN variability was analyzed and compared with reverse transcriptase (RT) and protease (PR) variability in
41 treatment naïve and 54 RT inhibitor (RTI) and protease inhibitor (PRI) experienced patients from subjects
infected with subtype B and non-B strains. In addition, four HIV-2 strains were analyzed in parallel. Frequency and
distribution of IN mutations were compared between HAART-naïve and RTI/PI-experienced patients; the genetic
barrier for 27 amino acid positions related to INI susceptibility was calculated as well.
Results: Primary mutations associated with resistance to INI were not detected in patients not previously treated
with this class of drug. However, some secondary mutations which have been shown to contribute to INI
resistance were found. Only limited differences in codon usage distribution between patient groups were found.
HIV-2 strains from INI naïve patients showed the presence of both primary and secondary resistance mutations.
Conclusion: Exposure to antivirals other than INI does not seem to significantly influence the emergence of
mutations implicated in INI resistance. HIV-2 strain might have reduced susceptibility to INI.
Background
Raltegravir (MK-0518; Isentress, Merck) was the first
integrase (IN) inhibitor approved for treatment of HIV
infection [1], while other compounds such as GS-9137
[2], S-1360 [3], and L-870,810 [4] are at different stages
of development. Raltegravir (RAL) has shown potent
and durable antiretroviral activity in both treatment
naïve [5,6] and highly experienced HIV-1-infected indi-
viduals. Due to its novel mechanism of action, RAL was
shown to be effective also against HIV-1 strains resistant
to reverse transcriptase (RT), protease (PR) and entry
inhibitors, both in vitro [7] and in vivo [8,9]. However, it
has been observed that failure of highly active antiretro-
viral therapy (HAART) including RAL might be related
to the emergence of drug-resistant virus variants [10-15],
and amino acid changes associated with resistance
to integrase inhibitors (INI) have been reported [16-18].
In particular, Y143R/C, N155H and Q148K/R/H have
been identified as primary RAL resistance mutations,
usually associated with secondary mutations often already
present at baseline [10, 12, and 13]. However, the entire
panel of mutations associated with RAL resistance has
not been fully ascertained. Nor do we fully understand
the potential impact of naturally occurring ancillary
mutations with respect to: i) promotion of RAL resistance
associated mutations, ii) improvement of the activity of
mutated IN and iii) HIV-1 replicative capacity. In addi-
tion, it is unclear whether drug pressure on the Pol gene
by RT and PR inhibitors might influence the emergence
of primary or ancillary RAL mutations. Finally, it has
been observed that about 20% of new HIV infections are
now sustained in Italy by a wide variety of subtype non-B
HIV-1 strains and a few HIV-2 strains [19,20]. Thus, it is
important to define the variability of the IN gene in treat-
ment-naïve and HAART-experienced patients in different
HIV-1 subtypes.
The aims of the study were: i) to evaluate IN variabil-
ity and polymorphism distribution among patients naïve
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any medium, provided the original work is properly cited.for RAL treatment; ii) to better understand whether pre-
vious HAART treatment not including RAL might be
associated with the emergence of mutations conferring
resistance to INI; iii) to calculate the genetic barrier of
primary and secondary mutations associated with INI
resistance in different HIV-1 subtypes.
Materials and methods
Patients
IN variability was analyzed using stored plasma samples
from 95 consecutive patients infected with HIV-1, as
well as four HIV-2 positive patients referred to our
Institution in the period December 2008 - December
2009. Patients with no available plasma samples or viral
load < 1,000 HIV RNA copies/ml plasma were excluded
from the analysis. Eligible patients were stratified on the
basis of treatment history as follows: i) HAART-naïve
patients, ii) RT and PR inhibitor-experienced but RAL-
naïve (RTI/PI-experienced).
Real-time RT-PCR, RT-PCR and sequencing
HIV-1 plasma RNA levels were determined using the
Versant HIV-1 RNA 3.0 Assay (Bayer, NY, USA), while
HIV-2 plasma RNA levels were determined according to
an in house developed real-time RT PCR [21]. For IN
gene sequencing (codons 1-277), a region of the HIV-1
Pol gene was amplified in a nested-RT-PCR using pri-
mers Int1F, 5’- CAT GGG TAC CAG CAC ACA CAA
AGG-3’ and Int1R, 5’-CCA TGT TCT AAT CCT CAT
CCT GTC -3’ for the first PCR round, while primers
Int2F 5’-GGA ATT GGA GGA AAT GAA CAA GTA
GAT -3’ and Int2R 5’- G C CA C AC A AT C AT C AC C T
GCC ATC-3’ were used in the second PCR round [12].
The first nested-RT-PCR reaction was performed in 50
μlu s i n gt h eS u p e r S c r i p t ™ III Platinum
® One-Step
qRT-PCR System (Invitrogen, Carlsbad, CA, USA) with
the following thermal profile: 30 min at 50°C and
10 min at 95°C for 1 cycle, 1 min at 95°C, 1 min at 52°
C and 1 min and 10 sec at 72°C for 50 cycles followed
by 10 min at 72°C. The nested PCR reaction was per-
formed in 100 μl using TaqGold and the relevant buffer
(Applied Biosystem, Foster City, CA, USA) with the fol-
lowing thermal profile: 10 min at 95°C for 1 cycle,
1 min at 95°C, 1 min at 50°C, and 1 min and 10 sec at
72°C for 30 cycles, followed by 10 min at 72°C [12]. RT
and PR genes were sequenced in parallel [22]. Sequen-
cing of amplicons was performed using an ABI PRISM
3100 Genetic Analyzer
® (Applied Biosystem, Foster
City, CA, USA) with the ABI PRISM™ Big Dye Termi-
nator Cycle Sequencing Reaction kit.
Sequence analysis
IN, RT, and PR sequences were analyzed with the
MEGA 4.0 version software [23]. Sequence distances
were calculated using the Simmonic sequence editor
(version 1.6) program [24], with the Kimura 2-Parameter
as a distance estimated method. Divergence was defined
as the mean proportion of nucleotide or amino acid dif-
ferences between all sequence pairs. In each patient,
only the predominant virus strain was taken into
account to calculate variability. Integrase variability was
also calculated in three functional domains: N-terminal
domain (NTD), catalytic core domain (CCD), and
C-terminal domain (CTD).
Genotypic resistance and genetic barrier
Resistance to antiretrovirals was estimated on the basis of
the Stanford HIV drug resistance database report (http://
hivdb.stanford.edu) and the geno2pheno
® report (http://
integrase.bioinf.mpi-inf.mpg.de/index.php). Twenty-seven
IN positions related to 28 mutations in INI resistant
HIV-1 strains were categorized as follows: i) primary
mutations (E92Q, F121Y, E138A, G140A/S, Y143R/C/H,
S147G, Q148H/R/K, S153Y, N155H, R263K) ii) ancillary
mutations (H51Y, T66I, L74A/M/I, Q95K, T97A,
E138K, Q146P V151I, E157Q,G163R, I203M, S230R)
and iii) mutations with an uncertain role (V72I,
T125K, A128Y, K160D, V165I, V201I; http://hivdb.
stanford.edu).
The genetic barrier to INI-resistance was calculated in
27 IN amino acid positions with a method previously
published by van de Vijver et al. [25]. The smallest
number of transitions (scored as 1) or transversions
(scored as 2.5) were used to calculate the genetic barrier.
The genetic barrier was calculated with the sum of
scores obtained for each amino acid position.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism (version 4.0) software (San Diego, CA, USA). To
compare the nucleotide and amino acid divergence
between groups of patients the Mann Whitney U-test
was utilized, while the chi-square test was used for com-
paring the calculated genetic barrier for major and
minor substitutions between groups of patients.
Results
Study population
Nucleotide (nt) and amino acid (aa) integrase variability
was analyzed in 41 HAART-naïve patients, and 54 RTI/
PI-experienced patients. Four HIV-2 strains were also
analyzed. Among HIV-1 strains from HAART-naïve
patients, 16 were subtype B and 25 were non-B strains
( A ,n o . 3 ;C ,n o . 5 ;G ,n o . 3 ;F ,n o . 6 ;C R F 0 2 A G ,n o . 6 ;
CRF01AE, no.1; CRF12BF, no.1;). Among HIV-1 strains
from RTI/PI-experienced patients, 19 were subtype B
and 35 were subtype non-B strains (A, no.1; A/K no. 2;
C, no.2 D, no.3; G, no.3; D/F, no.1; F, no.11; CRF02AG,
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son, RT and PR gene sequence variability was analyzed
in HAART-naïve and RTI/PI-experienced patients
(Table 1). HIV-2 strains were from RTI/PI-experienced
patients.
HIV IN, RT, and PR variability
Both IN nucleotide and amino acid variability was
higher in HAART-naïve patients with respect to RTI/PI-
experienced patients (p < 0.001; Table 1). Conversely,
RT and PR nucleotide variability was higher in RTI/PI-
experienced patients with respect to HAART-naïve
patients (p < 0.001).
Gene variability in the HIV-1 B and non-B subtypes
was also analyzed. In subtype B strains, IN amino acid
variability was statistically higher in HAART-naïve
patients with respect to RTI/PI-experienced patients
(6.1 ± 1.5 vs 4.1 ± 1.3; p < 0.001). However, both RT
(8.3 ± 2.3 vs 4.5 ± 1.2; p < 0.001) and PR (20.3 ± 7.5 vs
8.9 ± 2.8; p < 0.001) amino acid variability was higher in
strains from RTI/PI-experienced patients with respect to
HAART-naïve patients. In subtype non-B strains, IN
amino acid variability was not statistically different in
naïve patients with respect to RTI/PRI experienced
patients (6.9 ± 1.9 vs 7.1 ± 1.8; p > 0.05), whereas RT
(8.0 ± 2.2 vs 7.0 ± 1.9; p < 0.001) and PR (13.3 ± 6.2 vs
10.8 ± 4.1; p < 0.001) amino acid variability was higher
in RTI/PI-experienced patients with respect to HAART-
naïve patients.
In Table 1, the number of conserved and variable
amino acid residues of the IN gene in each group of
virus strains is shown. The number of conserved resi-
dues in sequences from HAART-naïve patients and
RTI/PI-experienced patients was comparable (Table 1).
No differences between singleton sites and parsimony
informative sites were observed among the variable resi-
dues in all patient groups (Table 1).
When the three functional domains of the IN gene
were individually analyzed, the amino acid sequences
from HAART-naïve patients were slightly more con-
served than sequences from RTI/PI-experienced
patients. In the analysis of amino acid variability in the
three structural domains for all sequence categories, a
higher variability in the NTD with respect to the CCD
and the CTD was observed (p < 0.001; data not shown).
Frequency, distribution and genetic barrier of IN
resistance mutations
In Table 2, mutations in positions associated with INI
susceptibility are shown. The eight primary mutations
associated with RAL or elvitegravir (EGV) resistance
were not present in any of the strains from INI-naïve
patients.
In the 41 HAART-naïve patients, 6 secondary muta-
tions were found: V72I (22/41, 53.7%), L74A/M/I (3/41,
7.3%), E157Q (2/41, 4.9%), V165I (8/41, 19.5%), V201I
(30/41, 73.2%) I203M (2/41. 4.9%) (Table 2). Addition-
ally, five substitutions of unknown significance (T97S,
T125A/M/V, S153A, K160Q/R, S230N) were found.
In the 54 RTI/PI-experienced patients, 7 secondary
mutations were found: V72I (28/54, 51.9%), L74A/M/I
(4/54, 7.4%), T97A (2/54, 3.7%), E157Q (1/54, 1.9%),
V165I (10/54, 18.5%), V201I (38/54, 70.4%) and I203M
(1/54, 1.9%; Table 2). Besides, seven substitutions of
unknown significance (V72D, Q95R, T125A/V/P,
E138D, K160Q, G163E/N/A and S230N; Table 2) were
found. No statistical difference in the prevalence of sec-
ondary mutations between sequences from HAART-
naïve and RTI/PI-experienced patients was observed
(p < 0.05)
Analysis of codon usage distribution between
sequences from HAART-naïve and RTI/PI-experienced
patients showed that there was no significant difference
in the INI resistance mutations with the exception of
position 148 (Table 3). At this position, a significant dif-
ference in predominant codon usage (CAA vs CAG)
between sequences from HAART-naïve and RTI/PI-
experienced patients was shown (p = 0.01).
HIV-2 variability and mutation distribution
HIV-2 strains showed higher conservation with respect to
HIV-1 subtype B and non-B strains (p < 0.001). In detail,
in HIV-2 strains, 241/273 (88.3%) conserved sites and 32/
273 (11.7%) variable sites were observed (Table 1). The
analysis of four HIV-2 integrase genes showed that the
mean nucleotide and amino acid variability was 13.0% ±
1.1 and 7.9% ± 1.4, respectively. Three out of four HIV-2
strains analyzed (all from RTI/PI-experienced patients
but INI naïve) showed the presence of an E to T poly-
morphism, in a position where a primary mutation
(E138A normally associated with RAL-resistant HIV-1
strains) was detected. Three secondary mutations I72V,
E125D and S163D (Table 2) were also detected.
Discussion
The introduction of the new INI antiviral-drug class
[6,26] is an important step forward in the treatment of
HIV-1 infection [8]. Despite the success of HAART in
managing HIV-1 infection, the development and world-
wide spread of HIV-1 drug resistant strains remain ser-
ious issues. In this study, we analyzed the IN gene
variability in parallel with RT and PR variability with the
aim of evaluating whether HIV genetic background
influences the appearance of IN mutations. The distri-
bution of specific amino acids implicated in INI suscept-
ibility was also compared in different HIV-1 subtypes
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Category
(strain no.)
Mean nucleotide divergence ± SD Mean amino acid divergence ± SD IN conserved amino
acid (%)
IN variable amino
acid (%)
IN conserved amino acid in three
functional domains (%)
RT gene PR gene IN gene RT gene PR gene IN gene Singleton
a Parsimony
b NTD (1-50) CCD (51-212) CTD (213-277)
HAART-naïve (41) 9.2 ± 2.3 10.5 ± 2.9 8.8 ± 2.5 6.3 ± 1.8 11.3 ± 3.5 7.0 ± 1.8 180 (65.9) 36 (13.2) 57 (20.9) 26 (52.0) 114 (70.4) 40 (62.5)
RT/PI-experienced
(54)
9.8 ± 2.5 12.2 ± 3.6 8.3 ± 2.5 9.8 ± 2.6 18.8 ± 7.8 6.5 ± 1.9 170 (62.3) 39 (14.3) 64 (23.4) 26 (52.0) 103 (63.6) 41 (64.1)
HAART-naïve vs
RT/PI-experienced
p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 ns ns ns ns ns ns
HIV-2 (4) ND ND 13.0 ± 1.1 ND ND 7.9 ± 1.4 241(88.3) 9(3.3) 23 (8.4) 39 (78.0) 149 (91.9) 53 (82.8)
HIV-2 vs HIV-1 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
SD: standard deviation; ND: not done; ns: not significant; NTD: N-terminal domain; CCD: catalytic core domain; CTD: C-terminal domain; RT: reverse trancriptase; PR: protease; IN: integrase.
aA singleton site contains at least two types of amino acid with, at most, one occurring multiple times.
bParsimony-informative if it contains at least two types of amino acid, and at least two of these occur with a minimum frequency of two.
cSignificant p-values are reported.
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9and in patients naïve for treatment or exposed to RTI
and PI. The simultaneous evaluation of RT, PR and IN
identity showed that the IN gene had lower amino acid
variability. This would confirm the high level of inte-
grase sequence conservation reported by Rhee et al.
[27]. Moreover, the analysis of three functional integrase
domains showed only a small difference in the catalytic
core domain.
The evaluation of IN variability in different patient
categories showed no differences in subtype non-B and
a higher divergence in subtype B strains from HAART-
naïve compared with RTI/PI-experienced patients.
These results are in contrast with the previously
reported greater amino acid IN divergence in RT/PI-
experienced patients [28]. On the other hand, we
observed a greater RT and PR amino acid divergence in
both B and non-B strains from RTI/PI-experienced
patients with respect to HAART-naïve patients. These
findings are consistent with the hypothesis that multiple
rounds of positive selection by subsequent HAART regi-
mens including different RTI and PI, may lead to the
emergence of a wider number of RT and PR variants in
contrast with little or no change in the IN gene.
In keeping with previous studies [13,29-32] no pri-
mary IN mutations associated with INI susceptibility
were present in strains from INI-naïve patients.
Table 2 HIV-1 and HIV-2 amino acid polymorphisms at positions associated with INI (RAL and EGV) resistance
Mutation categories Known amino
acid substitution
Rate of INI resistance
mutations in INI-naïve
patients (%)
HIV-1 amino acid
substitution
HIV-2 clade A ROD
subtype consensus
HIV-2
substitution
(4 strains)
HAART-
naïve
(n = 41)
RTI/PI-
experienced
(n = 54)
Primary E92Q E
mutations F121Y F
E138A ST 3
G140A/S G
Y143R7C/H Y
S147G S
Q148H/R/K Q
S153Y A1 A
N155H N
R263K R
Secondary mutations H51Y H
T66I T
L74A/M/I 7 (7.4) I2/M1 I4 I
Q95K R1 R
T97A 2 (2.1) S1 A2 T
E138K D1 ST 3
Q146P N
V151I V
E157Q 3 (3.2) Q2 Q1 H
G163R E2/N1/A1 SG 2
I203M 3 (3.2) M2 M1 M
S230R/M N4 N2 G
Polymorphic and non-
polymorphic mutations
V72I 50 (52.6) I22 I28/D1 IV 2
T125K A19/M1/V1 A24/V4/P1 ED 2
A128T M
K160D Q1/R1 Q1 N
V165I 18 (18.9) I8 I10 I
V201I 68 (71.6) I30 I38 I
RTI: reverse trancriptase inhibitor; PI: protease inhibitor; INI: integrase inhibitor.
New polymorphisms are reported in boldface.
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Page 5 of 9Table 3 Codon distribution and calculated genetic barrier at 27 integrase inhibitor susceptible positions in HIV-1 INI-naïve patients
IN codon
position
Substitution Wild
type
codon
Codon % distribution Mutational
resistance
codon
Lower
score
IN codon
position
Substitution Wild
type
codon
Codon % distribution Mutational
resistance
codon
Lower
scores
HAART-
naïve
(n = 41)
RTI/PI-
experienced
(n = 54)
HAART-
naïve
(n = 41)
RTI/PI-
experienced
(n = 54)
51 H51Y CAT 98 100 TAT 1 143 Y143C TAC 90 90 TGC 1
CAC 2 0 TAC 1 TAT 10 10 TGT 1
66 T66I ACA 98 94 ATA 1 Y143R TAC 90 90 CGC 2
ACC 0 6 ATC 1 TAT 10 10 CGT 2
ACG 2 0 ATA 2 146 Q146P CAA 98 98 CCG 2.5
72 V72I GTT 32 31 ATT 1 CAG 2 2 CCA 2.5
GTC 15 6 ATC 1 Q146K CAA 98 98 AAA 2.5
GTA 0 6 ATA 1 CAG 2 2 AAG 2.5
GTG 0 4 ATA 2 147 S147G AGT 76 70 GGT 1
I72 ATT 41 45 0 AGC 24 30 GGC 2
ATC 12 2 0 148 Q148H CAA 80 96 CAT/C 2.5
ATA 0 4 0 CAG 20 4 CAT/C 2.5
D72 GAT 0 2 ATT 3.5 Q148K CAA 80 96 AAA 2.5
74 L74I CTG 72 78 ATA 3.5 CAG 20 4 AAG 2.5
CTA 10 15 ATA 2.5 Q148R CAA 80 96 CGA 1
TTA 10 2 ATA 2.5 CAG 20 4 CGG 1
TTG 2 0 ATA 3.5 151 V151I GTA 71 72 ATA 1
I74 ATT 0 0 0 GTG 29 28 ATA 2
ATA 2 7 0 153 S153Y TCT 76 87 TAT 2.5
M74 ATG 2 0 ATA 1 TCC 15 11 TAC 2.5
92 E92Q GAA 63 61 CAA 2.5 TCA 7 2 TAT/C 5
GAG 37 39 CAG 2.5 A153 GCC 2 0 TAC 5
95 Q95K CAA 32 28 AAA 2.5 155 N155H AAT 90 93 CAT 2.5
CAG 68 70 AAG 2.5 AAC 10 7 CAC 2.5
R95 CGG 0 2 AAG 3.5 N155S AAT 90 93 AGT 1
97 T97A ACA 98 96 GCA 1 AAC 10 7 AGC 1
A97 GCA 0 4 0 157 E157Q GAA 88 91 CAA 2.5
S97 TCA 2 0 GCA 2.5 GAG 7 7 CAG 2.5
121 F121Y TTC 90 98 TAC 2.5 Q157 CAA 5 2 0
TTT 10 2 TAT 2.5 160 K160D AAA 85 93 GAT/C 3.5
125 T125K ACA 27 18 AAG 2.5 AAG 11 5 GAT/C 3.5
ACT 10 4 AAA/G 5 R160 AGA 2 0 GAT 4.5
ACG 12 24 AAG 2.5 Q160 CAA 2 2 GAT/C 5
A125 GCA 44 33 AAA 3.5 163 G163R GGA 63 57 AGA 1
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9Table 3 Codon distribution and calculated genetic barrier at 27 integrase inhibitor susceptible positions in HIV-1 INI-na?ï?ve patients (Continued)
GCG 2 6 AAG 3.5 GGG 27 39 AGG 1
GCT 0 6 AAA/G 6 GGT 0 2 CGC,AGA/G 3.5
V125 GTG 0 7 AAG 3.5 E163 GAA 0 4 AGA 2
GTA 2 0 AAA 3.5 N163 AAC 0 2 CGC,AGA/G 3.5
M125 ATG 2 0 AAG 2.5 A163 GCG 0 2 CTG,AGG 3.5
P125 CCG 0 2 AAG 5 165 V165I GTA 56 52 ATA 1
128 A128T GCA 54 50 ACA 1 GTC 22 18 ATC 1
GCC 37 46 ACC 1 GTT 2 10 ATT 1
GCT 9 4 ACT 1 GTG 0 2 ATA 2
138 E138K GAA 100 98 AAA 1 I165 ATA 20 18 0
D138 GAC 0 2 AAA/G 3.5 201 V201I GTA 24 28 ATA 1
140 G140S GGA 46 37 AGT/C 3.5 GTG 2 2 ATA 2
GGC 44 46 AGC 1 I201 ATA 74 70 0
GGT 5 6 AGT 1 203 I203M ATA 95 98 ATG 1
GGG 5 9 AGT/C 3.5 M203 ATG 5 2 0
G140A GGA 46 37 GCA 2.5 230 S230R AGC 90 96 AAC 1
GGC 44 46 GCC 2.5 N230 AAC 10 4 0
GGT 5 6 GCT 2.5 263 R263K AGA 85 96 AAA 1
GGG 5 6 GCT/G 2.5 AGG 15 4 AAG 1
The amino acids differing from wild-type or expected mutant are in boldface.
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9However, in sequences from INI-naïve patients some
secondary mutations, which have been shown to contri-
bute to RAL resistance [28-31], were found. The low
prevalence and the equal distribution of these poly-
morphisms among the different groups of patients are
in contrast with the reported appearance of secondary
mutations in association with prior antiretroviral expo-
sure [28,31]. Thus, our results are in accordance with
findings by Garrido et al., [32] and suggest that the emer-
gence of RAL resistance mutations is weakly influenced
by prior exposure to antiretrovirals other than INI.
Finally, new polymorphisms (Q95R, and T97S) in
positions related to INI resistance were found. Whether
and how these mutations might influence viral fitness or
replication remains to be clarified.
The genetic barrier was calculated for 27 amino acid
positions related to INI susceptibility. The majority of
these positions were highly conserved. Our analysis
extends the results reported by Maïga et al [33] (includ-
ing only B and CRFD02_AG subtypes) to a wider collec-
tion of HIV-1 subtypes which reflects the evolving
epidemiology of this infection in our region [19]. Analy-
sis of codon usage distribution between sequences from
HAART-naïve and RTI/PI-experienced patients revealed
a single position (148), with a predominant difference in
codon usage. These findings suggest a marginal yet valid
influence of prior antiretroviral exposure on the genetic
barrier in our study population [33]. A larger dataset
would allow better definition of the role played by pre-
vious treatment with RTI and PI on INI susceptibility.
On the other hand, the great majority of patients on
HAART show complete suppression of peripheral viral
load, and the enrollment of 95 viremic patients required
1 year to be completed.
Due to the small number of HIV-2 sequences, our
analysis did not allow us to draw conclusions on HIV-2
variability. However, of particular interest was the detec-
tion of mutations in IN positions associated with RAL
resistance. This finding confirms and extends a previous
observation by Xu et al. [34]. The identification of INI-
resistance mutations in INI-naive patients infected with
HIV-2 highlights the urgent need for future studies on
HIV-2 and may necessitate avoidance of INI in the
treatment of these patients.
In conclusion, primary INI resistance-associated muta-
tions were not present in this population of INI naïve
HIV-1 infected individuals. Exposure to antivirals other
than INI does not seem to significantly influence the
emergence of mutations implicated in INI resistance.
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